155 related articles for article (PubMed ID: 16098836)
1. Assessing risk across the spectrum of patients with the metabolic syndrome.
Rosenson RS
Am J Cardiol; 2005 Aug; 96(4A):8E-10E. PubMed ID: 16098836
[TBL] [Abstract][Full Text] [Related]
2. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
Noto H; Chitkara P; Raskin P
J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436
[TBL] [Abstract][Full Text] [Related]
3. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Haffner SM
Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
[TBL] [Abstract][Full Text] [Related]
4. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study.
Ingelsson E; Pencina MJ; Tofler GH; Benjamin EJ; Lanier KJ; Jacques PF; Fox CS; Meigs JB; Levy D; Larson MG; Selhub J; D'Agostino RB; Wang TJ; Vasan RS
Circulation; 2007 Aug; 116(9):984-92. PubMed ID: 17698726
[TBL] [Abstract][Full Text] [Related]
5. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Appel SJ; Harrell JS; Davenport ML
J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Kinalska I; Gorska M
Metabolism; 2008 Nov; 57(11):1539-44. PubMed ID: 18940391
[TBL] [Abstract][Full Text] [Related]
7. Small, dense low-density-lipoproteins and the metabolic syndrome.
Rizzo M; Berneis K
Diabetes Metab Res Rev; 2007 Jan; 23(1):14-20. PubMed ID: 17080469
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven GM
Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
10. Adipocytokines and metabolic syndrome.
Matsuzawa Y
Semin Vasc Med; 2005 Feb; 5(1):34-9. PubMed ID: 15968578
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study.
Patel DA; Srinivasan SR; Xu JH; Chen W; Berenson GS
Metabolism; 2006 Nov; 55(11):1551-7. PubMed ID: 17046560
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
13. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
Haffner SM
Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.
Lara-Castro C; Fu Y; Chung BH; Garvey WT
Curr Opin Lipidol; 2007 Jun; 18(3):263-70. PubMed ID: 17495599
[TBL] [Abstract][Full Text] [Related]
15. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.
Trujillo ME; Scherer PE
J Intern Med; 2005 Feb; 257(2):167-75. PubMed ID: 15656875
[TBL] [Abstract][Full Text] [Related]
16. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
Matsuzawa Y
Nat Clin Pract Cardiovasc Med; 2006 Jan; 3(1):35-42. PubMed ID: 16391616
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome and cardiovascular disease.
Bonora E
Ann Med; 2006; 38(1):64-80. PubMed ID: 16448990
[TBL] [Abstract][Full Text] [Related]
18. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.
Targher G; Bertolini L; Rodella S; Lippi G; Franchini M; Zoppini G; Muggeo M; Day CP
Obesity (Silver Spring); 2008 Jun; 16(6):1394-9. PubMed ID: 18369343
[TBL] [Abstract][Full Text] [Related]
19. Glucose, insulin, diabetes and mechanisms of arterial dysfunction.
Cameron JD; Cruickshank JK
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):677-82. PubMed ID: 17581229
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
